| ￥1200 | |
| A03055 | |
|
|
|
|
|
|
|
|
|
| Specificity | This product is specific to p-CRK (Y221) |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human CRK around the phosphorylation site of Y221 |
| Species Reactivity | Human |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||||
|
|||||||
| Form | Liquid |
| Storage Buffer | Supplied in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| Storage Instructions | Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. |
| Purification | Affinity-chromatography |
| Isotype | Rabbit IgG |
| Clonality | Monoclonal |
| Target Background | The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4. May regulate the EFNA5-EPHA3 signaling. |
| Synonyms | Adapter molecule crk; avian sarcoma virus CT10 (v-crk) oncogene homolog; CRK; CRKII; Proto-oncogene c-Crk; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
